Bracket with medical coating for preventing and treating restenosis and preparation method thereof

Abstract

The invention discloses a bracket with a medical coating for preventing and treating restenosis. The bracket comprises a support and the medical coating, wherein the medical coating covers the surface of the support. The bracket is characterized in that the effective components in the medical coating are guaiane sesquiterpenes compounds P1, P2 and P3, P1 is Zedoalactone B, P2 is a stereisomer of P1 and P3 is Zedoarondiol. Researches show that compared with the existing rapamycin bracket, the bracket not only can inhibit proliferation of endangium after the bracket is implanted, but also can inhibit inflammatory reaction of vascular walls and promote endothelialization of blood vessels, so that the bracket is beneficial to preventing forward thrombotic complications and is few in use level, low in cost and free from toxic and side effects.

Description

technical field [0001] The invention relates to the field of pharmaceutical medical devices, in particular to a stent with a drug coating for preventing restenosis and a preparation method thereof. Background technique [0002] Currently, percutaneous coronary intervention (PCI) is the main method for treating coronary heart disease. However, due to the unclear atherosclerosis mechanism of the coronary artery itself, as well as the potential damage caused by mechanical expansion and metal stent placement, local blood vessels produce inflammation and excessive healing responses to the injury, resulting in negative vascular remodeling and smooth muscle cell migration. In-stent restenosis (ISR) is formed after PCI, and the restenosis rate after stent placement can reach 15% to 40%. [0003] In order to prevent the formation of restenosis, the drug-eluting stent (DES) developed in the past is also called drug-releasing stent, which carries the drug through the polymer coated on...

AI Technical Summary

Problems solved by technology

Several clinical trials and meta-analysis results show that such drug-eluting stents may increase the incidence of death or myocardial infarction (stent thrombosis), affecting long-term prognosis, and the incidence of cardiac events after interventional therapy for acute myocardial infarction About 20%, and the incidence of restenosis with western drug-coated stents is still about 10%

In addition, this type of drug-coated stent is expensive, and an imported stent is about 20,000 yuan, which is not suitable for promotion in my country's national conditions, which increases medical costs and the economic burden of patients

[0005] In view of the pathophysiological mechanism of restenosis, drug-coated stents with antithrombotic, anti-inflammatory, anti-cell migration and proliferation effects should have the effect of preventing restenosis in theory, but the application of these drug-coated stents after PCI Disappointing study results: Although effective in reducing restenosis, some of these drugs have serious toxicity and side effects

Images